Skip to content
approvedGI & Metabolic

Plecanatide

Also known as: Trulance, SP-304

Plecanatide is a 16-amino-acid synthetic analog of human uroguanylin that acts as a guanylate cyclase-C (GC-C) agonist with pH-sensitive binding. FDA-approved in 2017 as Trulance, it treats chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Unlike linaclotide (which mimics guanylin/uroguanylin broadly), plecanatide was specifically designed to replicate the structure and pH-dependent activity of endogenous uroguanylin, potentially offering a more physiological mechanism with slightly lower rates of diarrhea.

3 cited references·5 researched benefits

Quick Answer

Plecanatide (Trulance) is a 16-amino-acid uroguanylin analog FDA-approved for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). As a guanylate cyclase-C agonist, it stimulates intestinal fluid secretion and accelerates transit. Its unique pH-sensitive design means it is most active in the mildly acidic environment of the proximal small intestine (pH 5–6), mimicking how endogenous uroguanylin works. This may contribute to lower rates of diarrhea compared to linaclotide.

Key Facts

Mechanism
Plecanatide is a structural analog of human uroguanylin with a single amino acid substitution (Leu→Asp at position 3) that preserves pH-dependent GC-C binding. In the proximal duodenum (pH 5–6), plecanatide adopts an active conformation and binds GC-C with high affinity. As intestinal pH increases distally (pH 7–8), binding affinity decreases, theoretically limiting activity to the proximal small intestine where uroguanylin normally acts. GC-C activation increases intracellular cGMP, which opens CFTR chloride channels, driving chloride, bicarbonate, and water secretion into the lumen. This softens stool and accelerates transit. Extracellular cGMP also inhibits visceral pain afferents, reducing abdominal pain. Like linaclotide, plecanatide has minimal systemic absorption (<1%) and acts almost entirely within the intestinal lumen.
Research Status
approved
Half-Life
Minimal systemic exposure (acts locally in the GI tract; degraded by intestinal proteases)
Molecular Formula
C₆₅H₁₀₄N₁₈O₂₆S₄
Primary Use
GI & Metabolic
Table of Contents

Benefits

  • CIC treatment — significantly increases complete spontaneous bowel movements (CSBMs) vs. placebo in two large phase 3 trials (lasting 12 weeks)strong
  • IBS-C symptom improvement — combined endpoint of abdominal pain reduction and increased CSBMs achieved in phase 3 IBS-C trialsstrong
  • pH-sensitive design — preferential activity in the proximal small intestine may result in a more physiological action and potentially lower diarrhea ratesstrong
  • Minimal systemic absorption — local GI action with <1% bioavailability and no clinically relevant systemic side effectsstrong
  • Visceral pain reduction — extracellular cGMP-mediated inhibition of colonic nociceptors reduces abdominal pain in IBS-C patientsmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Oral tablet (CIC)3 mgOnce dailyFDA-approved dose for chronic idiopathic constipation. Can be taken with or without food, unlike linaclotide which requires empty-stomach dosing. Tablet can be crushed and mixed with applesauce or administered via nasogastric tube for patients with swallowing difficulty.
Oral tablet (IBS-C)3 mgOnce dailySame dose as CIC indication. FDA-approved for IBS-C in adults. One of the practical advantages over linaclotide is the flexibility to take with or without food.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Diarrhea — occurs in 4–5% in CIC trials and ~4% in IBS-C trials; lower incidence than linaclotide in cross-trial comparisonscommon
  • Abdominal distension — mild bloating reported in 1–2% of patientscommon
  • Flatulence — gas and flatulence in 1–2% of patientscommon
  • Abdominal tenderness — mild tenderness or discomfort in the abdomencommon
  • Severe diarrhea with dehydration — rare but potentially serious; contraindicated in children <6 years old (neonatal mouse mortality in preclinical studies)serious

Frequently Asked Questions

How does plecanatide differ from linaclotide?
Both are GC-C agonists approved for CIC and IBS-C, but they differ in key ways: (1) Structure: linaclotide is a 14-amino-acid guanylin analog; plecanatide is a 16-amino-acid uroguanylin analog. (2) pH sensitivity: plecanatide has pH-dependent binding (most active at pH 5–6 in the proximal intestine); linaclotide is pH-independent. (3) Dosing: plecanatide can be taken with or without food; linaclotide requires empty-stomach dosing. (4) Diarrhea rates: plecanatide shows ~4–5% diarrhea rates vs. 14–20% for linaclotide (cross-trial comparison, not head-to-head). (5) Formulation: plecanatide is a tablet (crushable); linaclotide is a capsule (must be swallowed whole).
What is uroguanylin and why does plecanatide mimic it?
Uroguanylin is an endogenous 16-amino-acid peptide hormone produced by intestinal epithelial cells. It acts as a natural GC-C agonist that regulates intestinal fluid balance and electrolyte homeostasis. Uniquely, uroguanylin has pH-sensitive binding — it is most active at the mildly acidic pH of the proximal small intestine (pH 5–6), where most fluid absorption occurs. Uroguanylin also circulates to the kidneys where it promotes sodium excretion (natriuresis), linking gut salt sensing to renal function. Plecanatide was designed to closely replicate uroguanylin's structure and pH-dependent activity, aiming for a more physiological treatment approach than the guanylin-based linaclotide.
Can plecanatide be taken with food?
Yes. Unlike linaclotide, which must be taken on an empty stomach at least 30 minutes before the first meal, plecanatide can be taken with or without food. This is a significant practical advantage for patient convenience and adherence. The pH-sensitive activation of plecanatide means its activity profile is less affected by the presence of food, since it activates based on the local pH environment of the proximal intestine rather than food-mediated stimulation of GI secretory processes.
Is there a link between GC-C agonists and colorectal cancer prevention?
Emerging preclinical and epidemiological evidence suggests that GC-C signaling may have tumor-suppressive properties in the colon. Endogenous guanylin and uroguanylin expression is lost early in colorectal carcinogenesis (silenced in >85% of colorectal cancers), and restoring GC-C signaling in animal models inhibits tumor formation. Elevated intracellular cGMP from GC-C activation promotes epithelial cell differentiation, inhibits proliferation, and sensitizes cells to apoptosis. While this is a promising area of research, GC-C agonists are not approved or recommended for cancer prevention, and clinical trials are needed to determine whether long-term linaclotide or plecanatide use affects colorectal cancer risk in humans.

References

  1. 1
    Plecanatide for chronic idiopathic constipation: results of two phase 3, randomized, double-blind, placebo-controlled trials(2017)PubMed ↗
  2. 2
    Plecanatide for the treatment of irritable bowel syndrome with constipation: efficacy and safety in a randomized phase 3 trial(2018)PubMed ↗
  3. 3
    Uroguanylin and guanylate cyclase-C: from physiology to the GC-C agonist class of therapeutics(2014)PubMed ↗

Latest Research

Last updated: 2026-02-19